Hutchison M - Search Results

1

Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects.

Bui K, She F, Hutchison M, Brunnström Å, Sostek M. Bui K, et al. Among authors: hutchison m. Int J Clin Pharmacol Ther. 2015 Oct;53(10):838-46. doi: 10.5414/CP202276. Int J Clin Pharmacol Ther. 2015. PMID: 26329350 Free PMC article. Clinical Trial.

2

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, Giles P. Martin P, et al. Among authors: hutchison m. Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011. Epub 2011 Dec 28. Clin Ther. 2012. PMID: 22206795 Clinical Trial.

3

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.

McKillop D, Partridge EA, Hutchison M, Rhead SA, Parry AC, Bardsley J, Woodman HM, Swaisland HC. McKillop D, et al. Among authors: hutchison m. Xenobiotica. 2004 Oct;34(10):901-15. doi: 10.1080/00498250400009189. Xenobiotica. 2004. PMID: 15764410

4

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, Herron W, Swaisland HC. McKillop D, et al. Among authors: hutchison m. Xenobiotica. 2004 Oct;34(10):917-34. doi: 10.1080/00498250400009171. Xenobiotica. 2004. PMID: 15764411 Clinical Trial.

5

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M. McKillop D, et al. Among authors: hutchison m. Xenobiotica. 2006 Jan;36(1):29-39. doi: 10.1080/00498250500523253. Xenobiotica. 2006. PMID: 16507511

6

In vitro metabolism of gefitinib in human liver microsomes.

McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ, Bushby N, Hutchison M. McKillop D, et al. Among authors: hutchison m. Xenobiotica. 2004 Nov-Dec;34(11-12):983-1000. doi: 10.1080/02772240400015222. Xenobiotica. 2004. PMID: 15801543

7

Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.

Samuelsson K, Pickup K, Sarda S, Swales JG, Morikawa Y, Schulz-Utermoehl T, Hutchison M, Wilson ID. Samuelsson K, et al. Among authors: hutchison m. Xenobiotica. 2012 Nov;42(11):1128-37. doi: 10.3109/00498254.2012.689888. Epub 2012 May 30. Xenobiotica. 2012. PMID: 22642803

8

The pharmacokinetics of meropenem in volunteers.

Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. Bax RP, et al. Among authors: hutchison m. J Antimicrob Chemother. 1989 Sep;24 Suppl A:311-20. doi: 10.1093/jac/24.suppl_a.311. J Antimicrob Chemother. 1989. PMID: 2808215 Clinical Trial.

9

A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.

Jones HK, Kelly HC, Hutchison M, Yates RA, Ross F, Lomax C, Freestone S, Webb D. Jones HK, et al. Among authors: hutchison m. Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22(3):193-9. doi: 10.1007/BF03189806. Eur J Drug Metab Pharmacokinet. 1997. PMID: 9358198

10

A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

Kelly HC, Hutchison M, Haworth SJ. Kelly HC, et al. Among authors: hutchison m. J Antimicrob Chemother. 1995 Jul;36 Suppl A:35-41. doi: 10.1093/jac/36.suppl_a.35. J Antimicrob Chemother. 1995. PMID: 8543497

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters